Vilobelimab

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Vilobelimab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2025. DrugCentral lists 1 molecular target, including C5. Recorded indications include SARS-CoV2-induced acute respiratory distress syndrom.

• Molecular targets: C5 (1 listed in DrugCentral).
• Indications: SARS-CoV2-induced acute respiratory distress syndrom.
• ATC code: L04AJ10 (Complement inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• SARS-CoV2-induced acute respiratory distress syndrom

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Complement C5	C5	other	Kd 9.59

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2025-01-13	EMA	—	InflaRx GmbH

ATC classification

ATC code	Therapeutic hierarchy
L04AJ10	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: 137254326

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vilobelimab used for?

DrugCentral lists the following indications for Vilobelimab: SARS-CoV2-induced acute respiratory distress syndrom.

How does Vilobelimab work?

Its molecular targets in DrugCentral include C5.

When was Vilobelimab first approved?

Vilobelimab was first approved by the EMA in 2025.

Sources

• DrugCentral drug card 5761 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2109636 — compound record and bioactivity
• PubChem CID 137254326 — chemical identifiers
• DrugBank DB16416 — drug record
• FDA UNII F5T0RF9ZJA — substance identity
• UniProt P01031 (C5) — target protein

How this page is built: methodology · editorial policy & corrections.